The U.S. government is increasingly focused on health care policy reforms, causing pharmaceutical companies to rethink their strategies and tactics in pursuing “share of scripts.” For pharmaceutical companies, these reforms represent a paradigm shift in the structure of the U.S. market, and call for innovative approaches to commercialization and pricing. In a new value-driven health care system, pharmaceutical companies’ drug therapies will need to provide products that demonstrate measurable value to a broader array of stakeholders – physicians, patients, and payers. As a result, companies are faced with an increased need for engaging in discussion across the entire stakeholder ecosystem.
This case study highlights one pharmaceutical organization’s Medical Affairs team that addressed this stakeholder engagement need through an innovative approach.
The virtual sessions are wonderful in that we can answer topic questions at our own pace. We are extremely busy and this format is very accommodating.Physician Advisor Participant